1

News

IRSA CIRSE Registrar/IR fellow presentation awards 2019

Submissions for the IR fellows/registrar presentations are open.This year a considerable prize is being awarded jointly by IRSA and CIRSE.

Details here

60 Young Interventional Radiologist & Young Researchers awards APCIO 2019

The Organising Chairman of the 6th Asia-Pacific Congress of Interventional Oncology (APCIO) 2019 and President of the Malaysian Society of Interventional Radiology (MYSIR), are excited to announce the 6th Asia-Pacific Congress of Interventional Oncology (APCIO) 2019 in Kuala Lumpur, Malaysia from the 3rd - 5th October. Details of the conference can be found here

The conference is a multidisciplinary and multinational collaborating exercise involving interventional oncology, diagnostic radiology, medical oncology, radiation oncology, modern pathology, hepatology, gastroenterology, respiratory, and the related surgical disciplines, etc. The theme of the congress is “Interventional Therapy in Modern Oncology: Technological Integration Beyond Boundaries”,

The main aim of the congress is nurturing the next generation of IRs in Asia Pacific regions,and APCIO are pleased to announce they have confirmed 60 Young Interventional Radiologist & Young Researchers awards to present, and with the support of the Government of Malaysia, more awards will be added. Two training scholarships at a value of USD 3000 will also be awarded to the best papers, with their training being provided in renowned centres in Asia Pacific region.

Updated Updated CIRSE Position Statement on the use of paclitaxel-coated balloons and stents in peripheral arterial disease (PAD)

Recent debates at various global meetings, corrections to original papers and an FDA update suggest that there is a safety signal associated with the use of paclitaxel-coated balloons and stents in PAD patients. A preliminary review by the FDA of the three pivotal RCTs (975 patients with 5-year follow-up data) comparing paclitaxel-coated balloons or stents with standard balloon angioplasty or uncoated stents has confirmed a higher mortality in patients treated with paclitaxel products. There was an approximate 50% increased crude risk of mortality in patients treated with paclitaxel products.

The latest FDA update can be found on this link

Clearly, these results are preliminary and should be interpreted with caution. The trials involved mainly claudicants, and involved exclusively femoropopliteal lesions and not BTK lesions.

Moreover, a specific cause and mechanism of the increased mortality is unknown, few trials have long term follow-up data and it will take more time and possibly new trials to determine the veracity of the increased safety signal.

In the meantime, and until more information is available, CIRSE sees no alternative but to take the position that:

1. In the majority of patients undergoing lower limb recanalization therapies, alternatives to drug eluting devices should be used.
2. For some individual patients at particularly high risk for restenosis, clinicians may decide that the benefits of using a paclitaxel-coated device may outweigh the risks.
3. Drug-eluting devices should only be used after a full informed consent process that has discussed the mortality implications from the Katsanos meta-analysis (1).
4. All patients who have already received paclitaxel-eluting devices should be followed up to assess for a potential effect on mortality.

(1) Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018

Updated CIRSE Position Statement

Updated CIRSE Position Statement on the use of paclitaxel-coated balloons and stents in peripheral arterial disease

Dear IRSA members

IRSA would like to draw your attention to the following updated CIRSE press release regarding Paclitaxel coated and

eluting devices in the treatment of peripheral vascular disease. Further information can be found here.

 

 

FDA Update

UPDATE: Treatment of Peripheral Arterial Disease with Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents Potentially Associated with Increased Mortality - Letter to Health Care Providers

IRSA would like to draw the attention of its members to the following press reserve from the FDA regarding the use of paclitaxel coated balloons and eluting stents in peripheral vascular disease. 

FDA Update